Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day

Informations

• Publié par: redington-inc
• Nombre de lectures: 15
• Langue: English

Extrait

Keryx Biopharmaceuticals Announces Live

Webcast of Upcoming Analyst Day

PR Newswire

NEW YORK, June 19, 2012

NEW YORK

,

June 19, 2012

/PRNewswire/ -- Keryx Biopharmaceuticals, Inc.

(Nasdaq: KERX) today announced that its upcoming Analyst Day will be webcast

live on

Thursday, June 21, 2012

at

4:30 pm ET

. Scheduled speakers include:

Julia Lewis, M.D.

, will provide her perspective on the Zerenex (ferric citrate)

Phase 3 clinical program and the potential Zerenex product profile.

-- Professor of Medicine, Division of Nephrology, Vanderbilt University School of

Medicine.

Geoffrey Block, M.D.

, will discuss the potential for Zerenex in pre-dialysis.

-- Director of Research, Denver Nephrology and Associate Clinical Professor in

Medicine, University of Colorado Health Sciences Center.

David Goldfarb, M.D.

, will discuss the potential importance of citrate.

-- Chief, Nephrology Division, NY Campus of NY Harbor Health Care Veterans

Affairs System and Professor of Medicine & Physiology, NYU School of Medicine.

To access the live audio webcast, please visit the Company's Investor Relations

section of their website (http://investors.keryx.com). An archived version of the

webcast will become available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and

commercialization of medically important pharmaceutical products for the

treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral,

ferric iron-based compound that has the capacity to bind to phosphate and

form non-absorbable complexes. The Phase 3 clinical program of Zerenex for

the treatment of hyperphosphatemia (elevated phosphate levels) in patients

with end-stage renal disease is being conducted pursuant to a Special Protocol

Assessment (SPA) agreement with the FDA. Keryx is headquartered in

New York

City

.

KERYX CONTACT:

Lauren Fischer

Director - Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: [phone]

E-mail: [e-mail]